Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (463)	12/20/2002 10:50:44 AM
From: Icebrg	Read Replies (1) \| Respond to of 1022

PRESS RELEASE 2002-12-20: BioInvent and ImmunoGen extend collaboration Lund, Sweden: BioInvent International AB (publ) and ImmunoGen, Inc. enter into an agreement for the cGMP-manufacturing of a second antibody for an anticancer therapeutic candidate. Under the agreement BioInvent will perform process development and cGMP-manufacturing (current Good Manufacturing Practice) of the antibody used in ImmunoGen's product candidate huMy9-6-DM1. huMy9-6-DM1 is in development by ImmunoGen for the treatment of Acute Myeloid Leukemia (AML). ImmunoGen, Inc. (Nasdaq: IMGN), located in Boston, Massachusetts develops innovative biopharmaceuticals for the treatment of cancer. BioInvent has since Q3 2001 successfully manufactured under cGMP another antibody for ImmunoGen that is used in a different anticancer product candidate. "We see the extended collaboration with ImmunoGen as a proof of their continued confidence in BioInvent's manufacturing capabilities. This strengthens our presence in the important US antibody market", comments Svein Mathisen, CEO of BioInvent. Comments: I don't think IMGN has released any PR on this in the US. It's a little bit surprising if BioInvent is going to manufacture a humanized antibody. That's not supposed to be their line of business. But as this product should have a fair chance (it's supposed to be a Mylotarg copy with a more stable linker) of reaching the market, it might actually make it all the way. Blood-borne cancer cells should be much easier to reach too, compared to the more or less impenetrable ones residing in solid tumors.